Symbols / ALZN
ALZN Chart
About
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.95M |
| Enterprise Value | 3.50M | Income | -6.47M | Sales | — |
| Book/sh | 1.15 | Cash/sh | 1.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -0.70 | PEG | — |
| P/S | — | P/B | 1.82 | P/C | — |
| EV/EBITDA | -0.60 | EV/Sales | — | Quick Ratio | 6.20 |
| Current Ratio | 6.58 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.67 | EPS next Y | -2.98 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-12-09 16:00 | ROA | -72.71% |
| ROE | -144.76% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.80M |
| Shs Float | 3.79M | Short Float | 6.14% | Short Ratio | 1.85 |
| Short Interest | — | 52W High | 10.17 | 52W Low | 1.58 |
| Beta | -0.24 | Avg Volume | 75.51K | Volume | 56.38K |
| Target Price | $28.00 | Recom | None | Prev Close | $2.03 |
| Price | $2.09 | Change | 2.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$28.00
Mean price target
2. Current target
$2.08
Latest analyst target
3. DCF / Fair value
$-17.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.08
Low
$28.00
High
$28.00
Mean
$28.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $28 |
| 2025-09-25 | main | Ascendiant Capital | Buy → Buy | $42 |
| 2025-08-21 | main | Ascendiant Capital | Buy → Buy | $45 |
| 2025-03-17 | main | Ascendiant Capital | Buy → Buy | $20 |
| 2024-12-16 | main | Ascendiant Capital | Buy → Buy | $32 |
| 2024-11-11 | main | Ascendiant Capital | Buy → Buy | $35 |
- Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan Wed, 19 Nov 2025 08
- Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq hu, 25 Sep 2025 07
- Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance Fri, 28 Mar 2025 07
- Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222 - Investing.com Wed, 08 Oct 2025 07
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga Wed, 18 Feb 2026 12
- Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks hu, 29 May 2025 07
- Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Stocktwits hu, 29 May 2025 07
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 26 Jan 2026 08
- Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq Mon, 22 Dec 2025 08
- Alzamend Neuro’s New Trials Spark Curiosity - StocksToTrade hu, 29 May 2025 07
- How To Stop Losing Money While Trading Stocks - timothysykes.com ue, 03 Jun 2025 07
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 09 Jan 2026 08
- ALZN Stock Price and Chart — NASDAQ:ALZN - TradingView Sat, 17 Jul 2021 07
- Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com ue, 18 Nov 2025 08
- Alzamend Neuro Mourns Loss of Director Andrew Woo - TipRanks ue, 18 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1851 | 3825 | — | Sale at price 2.07 per share. | AULT MILTON C III | Director | — | 2025-12-23 00:00:00 | D |
| 1 | 3333 | 7059 | — | Sale at price 2.12 per share. | HORNE WILLIAM B | Director | — | 2025-12-19 00:00:00 | D |
| 2 | 30 | 69 | — | Sale at price 2.29 per share. | MCGRATH LYNNE FAHEY | Director | — | 2025-10-23 00:00:00 | D |
| 3 | 121791 | 294548 | — | Sale at price 2.32 - 2.44 per share. | AULT MILTON C III | Director | — | 2025-10-09 00:00:00 | I |
| 4 | 61743 | 143244 | — | Conversion of Exercise of derivative security at price 2.32 per share. | AULT MILTON C III | Director | — | 2025-10-08 00:00:00 | I |
| 5 | 139412 | 344222 | — | Sale at price 2.45 - 2.49 per share. | AULT MILTON C III | Director | — | 2025-10-07 00:00:00 | I |
| 6 | 200000 | 464000 | — | Conversion of Exercise of derivative security at price 2.32 per share. | AULT MILTON C III | Director | — | 2025-10-07 00:00:00 | I |
| 7 | 123366 | 296789 | — | Sale at price 2.35 - 2.44 per share. | AULT MILTON C III | Director | — | 2025-10-03 00:00:00 | I |
| 8 | 100000 | 232000 | — | Conversion of Exercise of derivative security at price 2.32 per share. | AULT MILTON C III | Director | — | 2025-10-01 00:00:00 | I |
| 9 | 79628 | 184156 | — | Sale at price 2.31 - 2.33 per share. | AULT MILTON C III | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-30 00:00:00 | I |
Financials
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.45M | -9.89M | -14.85M | -12.32M |
| TotalUnusualItems | 0.00 | 4.00K | 62.42K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 4.00K | 62.42K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.51M | -9.95M | -14.88M | -12.36M |
| ReconciledDepreciation | 50.74K | 50.74K | 23.07K | 3.55K |
| EBITDA | -4.45M | -9.89M | -14.85M | -12.31M |
| EBIT | -4.50M | -9.94M | -14.87M | -12.32M |
| NetInterestIncome | -18.03K | -10.10K | -7.70K | -46.52K |
| InterestExpense | 18.03K | 10.10K | 7.70K | 46.52K |
| InterestIncome | 0.00 | 1.71K | ||
| NormalizedIncome | -4.51M | -9.95M | -14.88M | -12.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.51M | -9.95M | -14.88M | -12.36M |
| TotalExpenses | 4.50M | 9.94M | 14.87M | 12.32M |
| TotalOperatingIncomeAsReported | -4.50M | -9.94M | -14.87M | -12.32M |
| DilutedAverageShares | 450.80K | 75.17K | 65.01K | 66.00K |
| BasicAverageShares | 450.80K | 75.17K | 65.01K | 66.00K |
| DilutedEPS | -11.32 | -132.33 | -228.90 | -189.00 |
| BasicEPS | -11.32 | -132.33 | -228.90 | -189.00 |
| DilutedNIAvailtoComStockholders | -5.11M | -9.95M | -14.88M | -12.36M |
| NetIncomeCommonStockholders | -5.11M | -9.95M | -14.88M | -12.36M |
| PreferredStockDividends | 590.23K | |||
| NetIncome | -4.51M | -9.95M | -14.88M | -12.36M |
| NetIncomeIncludingNoncontrollingInterests | -4.51M | -9.95M | -14.88M | -12.36M |
| NetIncomeContinuousOperations | -4.51M | -9.95M | -14.88M | -12.36M |
| PretaxIncome | -4.51M | -9.95M | -14.88M | -12.36M |
| OtherIncomeExpense | 4.00K | 62.42K | ||
| SpecialIncomeCharges | 0.00 | 4.00K | 62.42K | |
| OtherSpecialCharges | -4.00K | -62.42K | ||
| NetNonOperatingInterestIncomeExpense | -18.03K | -10.10K | -7.70K | -46.52K |
| InterestExpenseNonOperating | 18.03K | 10.10K | 7.70K | 46.52K |
| InterestIncomeNonOperating | 0.00 | 1.71K | ||
| OperatingIncome | -4.50M | -9.94M | -14.87M | -12.32M |
| OperatingExpense | 4.50M | 9.94M | 14.87M | 12.32M |
| ResearchAndDevelopment | 1.41M | 6.46M | 7.45M | 5.20M |
| SellingGeneralAndAdministration | 3.08M | 3.48M | 7.42M | 7.12M |
| SellingAndMarketingExpense | 347.30K | 247.33K | 742.60K | 17.65K |
| GeneralAndAdministrativeExpense | 2.73M | 3.24M | 6.68M | 7.10M |
| OtherGandA | 964.62K | 1.12M | 1.28M | 1.23M |
| InsuranceAndClaims | 259.38K | 381.74K | 587.43K | 714.33K |
| SalariesAndWages | 1.51M | 1.74M | 4.82M | 5.16M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-04-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 778.73K | 76.44K | 71.81K | 70.73K |
| ShareIssued | 778.73K | 76.44K | 71.81K | 70.73K |
| TotalDebt | 300.71K | 335.30K | ||
| TangibleBookValue | 3.97M | -2.59M | 3.05M | 13.35M |
| InvestedCapital | 3.97M | -2.29M | 3.05M | 13.35M |
| WorkingCapital | 3.54M | -2.77M | 2.97M | 13.25M |
| NetTangibleAssets | 3.97M | -2.59M | 3.05M | 13.35M |
| CommonStockEquity | 3.97M | -2.59M | 3.05M | 13.35M |
| PreferredStockEquity | 75.00 | |||
| TotalCapitalization | 3.97M | -2.59M | 3.05M | 13.35M |
| TotalEquityGrossMinorityInterest | 3.97M | -2.59M | 3.05M | 13.35M |
| StockholdersEquity | 3.97M | -2.59M | 3.05M | 13.35M |
| OtherEquityInterest | -14.88M | -14.88M | -14.88M | |
| RetainedEarnings | -58.54M | -54.02M | -44.07M | -29.19M |
| AdditionalPaidInCapital | 62.50M | 51.43M | 62.00M | 57.42M |
| CapitalStock | 78.00 | 8.00 | 65.00 | 9.55K |
| CommonStock | 78.00 | 8.00 | 65.00 | 9.55K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 634.76K | 3.23M | 2.87M | 1.16M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 634.76K | 3.23M | 2.87M | 1.16M |
| CurrentDebtAndCapitalLeaseObligation | 300.71K | 335.30K | ||
| CurrentDebt | 300.71K | 335.30K | ||
| OtherCurrentBorrowings | 335.30K | |||
| CurrentNotesPayable | 0.00 | 300.71K | 0.00 | |
| PayablesAndAccruedExpenses | 634.76K | 2.93M | 2.87M | 1.16M |
| Payables | 634.76K | 2.93M | 2.87M | 1.16M |
| DuetoRelatedPartiesCurrent | 0.00 | 2.08K | 60.75K | |
| AccountsPayable | 634.76K | 2.93M | 2.87M | 1.16M |
| TotalAssets | 4.60M | 631.59K | 5.92M | 14.52M |
| TotalNonCurrentAssets | 425.61K | 176.35K | 79.84K | 102.91K |
| NetPPE | 425.61K | 176.35K | 79.84K | 102.91K |
| CurrentAssets | 4.18M | 455.24K | 5.84M | 14.41M |
| CurrentDeferredAssets | 352.50K | |||
| PrepaidAssets | 228.72K | 79.19K | 694.92K | 349.72K |
| Receivables | 0.00 | 16.21K | ||
| OtherReceivables | 16.21K | |||
| AccruedInterestReceivable | 0.00 | |||
| NotesReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 3.95M | 376.05K | 5.14M | 14.06M |
| CashAndCashEquivalents | 3.95M | 376.05K | 5.14M | 14.06M |
| CashFinancial | 3.95M | 376.05K | 5.14M | 14.06M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| FreeCashFlow | -6.87M | -8.42M | -8.92M | -6.72M |
| RepaymentOfDebt | 0.00 | -58.67K | -1.92K | |
| IssuanceOfDebt | 0.00 | 300.00K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 10.44M | 3.35M | 0.00 | 18.91M |
| CapitalExpenditure | -300.00K | -147.24K | -106.46K | |
| EndCashPosition | 3.95M | 376.05K | 5.14M | 14.06M |
| BeginningCashPosition | 376.05K | 5.14M | 14.06M | 1.93M |
| ChangesInCash | 3.57M | -4.76M | -8.92M | 12.13M |
| FinancingCashFlow | 10.44M | 3.65M | 200.00 | 18.85M |
| CashFlowFromContinuingFinancingActivities | 10.44M | 3.65M | 200.00 | 18.85M |
| NetOtherFinancingCharges | 1.95M | |||
| ProceedsFromStockOptionExercised | 600.00 | 0.00 | 200.00 | 2.20K |
| NetPreferredStockIssuance | 7.74M | 2.10M | 0.00 | |
| PreferredStockIssuance | 7.74M | 2.10M | 0.00 | |
| NetCommonStockIssuance | 2.70M | 1.25M | 0.00 | 18.91M |
| CommonStockIssuance | 2.70M | 1.25M | 0.00 | 18.91M |
| NetIssuancePaymentsOfDebt | 0.00 | 300.00K | 0.00 | -58.67K |
| NetShortTermDebtIssuance | 0.00 | 300.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 300.00K | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | -58.67K | 400.19K | |
| LongTermDebtPayments | 0.00 | -58.67K | -1.92K | |
| LongTermDebtIssuance | 0.00 | 402.11K | ||
| InvestingCashFlow | -300.00K | -147.24K | 0.00 | -106.46K |
| CashFlowFromContinuingInvestingActivities | -300.00K | -147.24K | 0.00 | -106.46K |
| NetOtherInvestingChanges | 100.92K | |||
| NetPPEPurchaseAndSale | -300.00K | -147.24K | 0.00 | -106.46K |
| PurchaseOfPPE | -300.00K | -147.24K | 0.00 | -106.46K |
| OperatingCashFlow | -6.57M | -8.27M | -8.92M | -6.61M |
| CashFlowFromContinuingOperatingActivities | -6.57M | -8.27M | -8.92M | -6.61M |
| ChangeInWorkingCapital | -2.44M | 670.67K | 2.35M | 1.33M |
| ChangeInPayablesAndAccruedExpense | -2.29M | 54.94K | 1.71M | 693.58K |
| ChangeInPrepaidAssets | -149.53K | 615.73K | 642.05K | 633.60K |
| OtherNonCashItems | 9.29K | 714.00 | 12.77K | 517.05K |
| StockBasedCompensation | 325.11K | 955.63K | 3.58M | 4.41M |
| DepreciationAmortizationDepletion | 50.74K | 50.74K | 23.07K | 3.55K |
| DepreciationAndAmortization | 50.74K | 50.74K | 23.07K | 3.55K |
| Depreciation | 50.74K | 50.74K | 23.07K | 3.55K |
| OperatingGainsLosses | -4.00K | -62.42K | ||
| NetIncomeFromContinuingOperations | -4.51M | -9.95M | -14.88M | -12.36M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALZN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|